Neuroimaging-Defined Amyloid and Cerebrovascular Pathology are Associated with 
a Neurometabolic Signature of Alzheimer's Disease

Schreiner, SJ; Kirchner, T; Narkhede, A; Wyss, M; Van Bergen, JMG; Steininger, SC; Gietl, AF; Leh, SE; Treyer, V; Buck, A; Pruessmann, KP; Nitsch, RM; Hock, C; Henning, A; Brickman, AM; Unschuld, PG

doi:10.1016/j.jalz.2017.06.2290

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Meeting Abstract

Neuroimaging-Defined Amyloid and Cerebrovascular Pathology are Associated with a Neurometabolic Signature of Alzheimer's Disease

MPS-Authors

/persons/resource/persons84402

Henning, A
Research Group MR Spectroscopy and Ultra-High Field Methodology, Max Planck Institute for Biological Cybernetics, Max Planck Society;

External Resource

Link
(Publisher version)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Schreiner, S., Kirchner, T., Narkhede, A., Wyss, M., Van Bergen, J., Steininger, S., et al. (2017). Neuroimaging-Defined Amyloid and Cerebrovascular Pathology are Associated with a Neurometabolic Signature of Alzheimer's Disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 13(7 Supplement): IC-P-018, P20-P21.

Cite as: https://hdl.handle.net/21.11116/0000-0000-C451-7

Abstract

Background: To investigate whether white matter hyperintensities (WMH), an MRI-correlate of small-vessel cerebrovascular disease, are associated with a neurometabolic signature of Alzheimer's disease (AD), defined as the metabolic correlates of preclinical ß-amyloid (Aß) pathology and the apolipoprotein-E ε4 allele (APOE-ε4), the major genetic risk factor for sporadic AD.
Methods: Cognitively normal participants (n=30, age=70±5.6 years, MMSE=29.2±1) received 11C-PiB-PET to quantify Aß, 7 Tesla fluid-attenuated inversion recovery MRI to quantitate WMH, and 7 Tesla high-resolution MR spectroscopic imaging to estimate N-acetylaspartate (NAA), myo-inositol (mI), total-choline (tCho), and creatine (Cr) in posterior cingulate and precuneus (PCP) gray and white matter. We examined relationships of Aß, WMH, and APOE-ε4, and their interactions, with brain metabolites.
Results: Higher levels of Aß (r= -0.64, p<0.001) and higher WMH volume (r= -0.45, p=0.02) were associated with lower NAA/mI in gray matter. Participants with both high Aß and high WMH had lower NAA/mI compared to those with none or with high level of either Aß or WMH (significant Aß x WMH interaction; F=5.38, p=0.03). APOE-ε4 carriers had lower NAA/mI compared to non-carriers (t=2.24, p=0.03). tCho/Cr in white matter was associated with Aß (r= -0.53 p=0.004) and WMH (r= -0.51; p=0.006); APOE-ε4 carriers with high WMH showed strongest reductions of tCho/Cr (significant APOE-ε4 x WMH interaction, F=6.45, p=0.02).
Conclusions: These findings suggest that a neurometabolic signature of AD, defined by metabolic correlates of Aß and APOE-ε4 in older adults, consists of reduced NAA/mI in gray matter and reduced tCho/Cr in white matter. We speculate that these metabolic differences reflect neuronal impairment, glial activation, and altered choline metabolism. This neurometabolic signature of AD is also associated with WMH, both independently and synergistically with Aß and APOE-ε4, emphasizing the importance of small-vessel cerebrovascular disease for AD pathogenesis.